Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Compulsory licences: necessity or threat?

23 May 2013 Comments

news image

Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?

Most Commented

Ultralight solar cells designed to drive drones

24 August 2015 Research

news image

Researchers have shown perovskite solar cells just 3μm thick can power miniature model aircraft

Elusive fermion found at long last

16 July 2015 Research

news image

Experimental observation of Weyl fermions in a tantalum arsenide crystal ends search after 86 years